Repurposing auranofin for the treatment of cutaneous staphylococcal infections

International Journal of Antimicrobial Agents
Shankar ThangamaniMohamed N Seleem

Abstract

The scourge of multidrug-resistant bacterial infections necessitates the urgent development of novel antimicrobials to address this public health challenge. Drug repurposing is a proven strategy to discover new antimicrobial agents; given that these agents have undergone extensive toxicological and pharmacological analysis, repurposing is an effective method to reduce the time, cost and risk associated with traditional antibiotic innovation. In this study, the in vitro and in vivo antibacterial activities of an antirheumatic drug, auranofin, was investigated against multidrug-resistant Staphylococcus aureus. The results indicated that auranofin possesses potent antibacterial activity against all tested strains of S. aureus, including meticillin-resistant S. aureus (MRSA), vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA), with minimum inhibitory concentrations (MICs) ranging from 0.0625μg/mL to 0.125μg/mL. In vivo, topical auranofin proved superior to conventional antimicrobials, including fusidic acid and mupirocin, in reducing the mean bacterial load in infected wounds in a murine model of MRSA skin infection. In addition to reducing the bacterial load, topical treatment of auranofin greatly r...Continue Reading

References

Feb 13, 2001·Trends in Microbiology·T F Mah, G A O'Toole
Jul 16, 2005·Clinical Microbiology Reviews·Bénédicte Fournier, Dana J Philpott
Oct 24, 2007·The Veterinary Clinics of North America. Small Animal Practice·Anthony J Mutsaers
May 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin E Stryjewski, Henry F Chambers
Jan 24, 2009·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Sarah Jackson-RosarioWilliam Thomas Self
Apr 25, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ana del RioJosé M Miró
Feb 2, 2011·Antimicrobial Agents and Chemotherapy·J Chase McNeilEdward O Mason
May 13, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David J FarrellIan Chopra
Jul 9, 2013·Critical Care Clinics·Yoav Keynan, Ethan Rubinstein
Jul 19, 2013·PloS One·Christopher P MontgomeryRobert S Daum
May 14, 2014·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Maria Iris CassettaLuigi Messori
May 24, 2014·Nature Reviews. Drug Discovery·Marc Y Donath
Jun 27, 2014·Nature·Andrew M KingGerard D Wright
Sep 18, 2014·The New England Journal of Medicine·Helen W BoucherMichael W Dunne
Nov 26, 2014·Antimicrobial Agents and Chemotherapy·Andrew F ShorrPhilippe Prokocimer
Mar 12, 2015·Current Pharmaceutical Design·Shankar ThangamaniMohamed N Seleem
Jun 27, 2015·Scientific Reports·Shankar ThangamaniMohamed N Seleem
Jul 5, 2015·The Journal of Antimicrobial Chemotherapy·Leire AguinagaldeJosé M Sánchez-Puelles
Jul 30, 2015·PloS One·Shankar ThangamaniMohamed N Seleem
Aug 19, 2015·Frontiers in Microbiology·Shankar ThangamaniMohamed N Seleem

❮ Previous
Next ❯

Citations

Oct 23, 2016·Biochimica Et Biophysica Acta. General Subjects·Shankar ThangamaniMohamed N Seleem
Jul 13, 2019·Future Medicinal Chemistry·Nagendran TharmalingamBeth B Fuchs
Mar 21, 2018·Frontiers in Microbiology·Holly C MayBernard P Arulanandam
Jan 23, 2020·Applied Microbiology and Biotechnology·Ram Anand VadlamaniAllen L Garner
Nov 11, 2019·Archives of Microbiology·Hye-In Jang, Yong-Bin Eom
Oct 2, 2019·Antimicrobial Agents and Chemotherapy·Marwa AlhashimiMohamed N Seleem
May 13, 2020·Antimicrobial Agents and Chemotherapy·Young Jin SeongMohamed N Seleem
Feb 13, 2019·Frontiers in Microbiology·Andrea Miró-CanturriYounes Smani
Feb 6, 2017·Frontiers in Cellular and Infection Microbiology·Shankar ThangamaniMohamed N Seleem
May 31, 2018·Scientific Reports·Ahmed AbdelKhalekMohamed N Seleem
Jul 10, 2018·Current Medicinal Chemistry·Ananda Kumar KonreddyYongseok Choi
Apr 1, 2017·Antimicrobial Resistance and Infection Control·Frank GüntherNico T Mutters
Mar 16, 2019·Frontiers in Cellular and Infection Microbiology·Hanyang LiuAnita Shukla
Apr 14, 2018·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Poulomi DeyAiyagari Ramesh
Dec 24, 2019·Medical Mycology·I F Abou-El-NagaS X A N X A El Achy
Sep 11, 2019·Archives of Dermatological Research·Shilpi Goenka, Sanford R Simon
Jun 3, 2017·The Journal of Antimicrobial Chemotherapy·A E J YsselH P Steenackers
Oct 24, 2020·Nanoscale·Ana V Morales-de-EchegarayAlexander Wei
Oct 14, 2020·Antimicrobial Agents and Chemotherapy·Christoph H R SengesJulia E Bandow
May 19, 2021·Chembiochem : a European Journal of Chemical Biology·Johannes Karges, Seth M Cohen
Aug 6, 2021·Advanced Healthcare Materials·William NdugireMingdi Yan
Aug 23, 2021·International Journal of Antimicrobial Agents·Alvie Loufouma MbouakaJulia Walochnik
Oct 3, 2018·International Journal of Antimicrobial Agents·Ahmed AbdelKhalekMohamed N Seleem

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.